Innovation Showcase Thursday morning
Drug development is a notoriously lengthy, expensive and inefficient process, with cardiotoxicity being a frequent cause for failure. Conventional non-human cell and animal models are poorly predictive of human responses, leading to false negative and positive results that compromise overall success rates. Novoheart’s MyHeartTM Platform aims to revolutionize this process, offering a hierarchy of bioartificial human pluripotent stem cell-derived heart tissue constructs designed as screening tools for predicting cardiotoxicity as well as drug efficacy. This includes our human ventricular Cardiac Anisotropic Sheet (hvCAS) assay for electrophysiology, our human ventricular Cardiac Tissue Strip (hvCTS) assay for contractility, and our unique human ventricular Cardiac Organoid Chamber (hvCOC, or “human heart-in-a-jar”) assay, the only macroscopic human cardiac model on the market capable of pumping fluid, with unprecedented biofidelity mimicking the native human heart. We will also introduce the new MyHeartTM Platform 2.0, which delivers additional value in terms of throughput, sensitivity and accuracy, with hardware and software innovations including machine learning for smart drug classification, markedly enhancing Novoheart’s capabilities for next-generation drug discovery.
Innovation Showcase: Novoheart
08:00 - 08:30
08:00 - 08:30
Innovation Showcase: MYHEART PLATFORM: UNVEILING NOVOHEART’S NEXT-GENERATION DRUG DISCOVERY TOOLS INCLUDING 3D BIOENGINEERED HUMAN HEART-IN-A-JAR - Novoheart